According to the Zhitong Finance APP, CHENGYIPHARMA (603811.SH) announced that it has recently received the &#34;Drug Supplement Application Approval Notice&#34; issued by the National Medical Products Administration. The sodium cytidine injection produced by the company has passed the consistency evaluation of generic drug quality and efficacy.
Sodium cytidine injection is mainly used for consciousness disorders after acute cranial trauma and brain surgery. As of the announcement date, the company has invested approximately RMB 4.2843 million (unaudited) in the consistency evaluation of this drug

603811

CHENGYIPHARMA announced that its sodium cytidine injection has passed the consistency evaluation of generic drugs by the National Medical Products Administration, mainly used for consciousness disorders after acute traumatic brain injury and brain surgery. The company's cumulative R&D investment in the consistency evaluation of this drug is approximately RMB 4.2843 million (unaudited)

CHENGYIPHARMA: Sodium Cytidine Diphosphate Injection has passed the consistency evaluation of generic drugs